Norepinephrine Kabi (Noradrenaline Tartrate)

Noradrenaline tartrate acts as a direct agonist at alpha‑1 and beta‑1 adrenergic receptors. Alpha‑1 activation causes peripheral vasoconstriction, while beta‑1 stimulation increases heart rate and contractility, together elevating systemic vascular resistance and cardiac output to raise arterial pressure.

The dose of Norepinephrine Kabi is individualized. A prescriber determines the infusion rate based on the patient’s blood pressure response, clinical condition, and monitoring data, and then adjusts the infusion to maintain the desired hemodynamic target.

The pregnancy category for noradrenaline tartrate is unknown. It should only be used during pregnancy or lactation when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

The primary alternatives are dopamine and phenylephrine. Norepinephrine provides stronger alpha‑1 mediated vasoconstriction with less tachycardia than dopamine, and offers combined alpha‑ and beta‑1 activity, whereas phenylephrine is a pure alpha‑1 agonist and may cause more pronounced reflex bradycardia.

Norepinephrine Kabi should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The solution should be kept in its original container until use and inspected for particulate matter before administration.

The product is supplied as a sterile solution for injection and is given by continuous intravenous infusion. It is typically diluted in a compatible carrier fluid and administered through a calibrated infusion pump, with the rate adjusted to achieve the target blood pressure.

Serious risks include severe hypertension, cardiac arrhythmias, myocardial ischemia, and peripheral ischemia due to excessive vasoconstriction. Continuous cardiovascular monitoring is essential to detect these events promptly and adjust therapy as needed.

Patients with known hypersensitivity to noradrenaline or any excipients, those with uncontrolled hypertension, or individuals in whom excessive vasoconstriction could compromise tissue perfusion should not receive Norepinephrine Kabi. Contraindications are determined by the treating physician.